89bio, Inc. Added to Russell Microcap Growth Index, Pegozafermin Development for NASH and SHTG Continues

89bio, Inc. has been added to the Russell Microcap Growth Index. The company is a clinical-stage biopharmaceutical firm focused on developing therapies for liver and cardio-metabolic diseases. Its lead product candidate, pegozafermin, is being developed for nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG) treatment. Pegozafermin is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) engineered to protect against proteolysis and reduce renal clearance.

89Bio, Inc., a clinical-stage biopharmaceutical firm, has been added to the Russell Microcap Growth Index. The company specializes in developing therapies for liver and cardio-metabolic diseases. Its lead product candidate, pegozafermin, is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) engineered to protect against proteolysis and reduce renal clearance [1].

The inclusion of 89Bio, Inc. in the Russell Microcap Growth Index reflects investor confidence in the company's pipeline and potential for growth. The index is designed to capture the performance of small-cap growth companies, making it an attractive benchmark for investors seeking exposure to innovative biopharmaceutical firms.

89Bio, Inc. is focused on addressing significant unmet medical needs in the liver and cardio-metabolic disease areas. Nonalcoholic steatohepatitis (NASH) is a progressive liver disease that affects millions of people worldwide, and severe hypertriglyceridemia (SHTG) is a condition associated with high triglyceride levels in the blood, which can lead to serious health complications.

Pegozafermin, the company's lead product candidate, is designed to target these conditions by leveraging the protective effects of FGF21. The glycoPEGylation process enhances the stability and half-life of the protein, making it more effective in treating NASH and SHTG. The company's approach to developing precision-targeted therapies aligns with the broader trend in biopharmaceuticals towards personalized and effective treatments.

The addition of 89Bio, Inc. to the Russell Microcap Growth Index is a testament to the company's potential to make a significant impact in the biopharmaceutical industry. As the company continues to advance its pipeline, investors will be closely watching its progress and the potential for pegozafermin to become a successful therapeutic option for patients with NASH and SHTG.

References:
[1] https://www.biospace.com/press-releases/a2-bio-announces-first-patient-dosed-in-denali-1-phase-1-2-clinical-study-of-a2b395-a-novel-allogeneic-precision-car-t-cell-therapy-for-patients-with-solid-tumors-that-express-egfr